Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 6, 2015, Pages 582-589

  Onuma, Shoko ^a   Honda, Hirokazu ^b   Kobayashi, Yasuna ^a   Yamamoto, Toshinori ^a   Michihata, Tetsuo ^c   Shibagaki, Keigo ^c   Yuza, Toshitaka ^c   Hirao, Keiichi ^c   Tomosugi, Naohisa ^d   Shibata, Takanori ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

^c Asahi Kasei Medical   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anemia; Continuous erythropoietin receptor activator; Darbepoetin ; Hepcidin 25; Soluble transferrin receptor

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; HEPCIDIN; HEPCIDIN 25; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ERYTHROPOIETIN; IRON; MACROGOL DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IRON METABOLISM; IRON STORAGE; IRON THERAPY; IRON TRANSPORT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; REGULATORY MECHANISM; RETICULOCYTE COUNT; BLOOD; HEMODIALYSIS; METABOLISM; MIDDLE AGED;

AGED; BIOMARKERS; DARBEPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; TRANSFERRIN;

EID: 84983150625     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12322     Document Type: Article

References (27)

1. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002;32(Suppl 1):S70-S78.
2. Kuo KL, Hung SC, Lee TS, Tarng DC. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014;25:2596-2606.
3. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS ONE 2013;8:e78930.
4. Drüeke T, Witko-Sarsat V, Massy Z etal. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-2217.
5. Kuo KL, Hung SC, Lin YP etal. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 2012;7:e50295.
6. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-3080.
7. Hasuike Y, Nonoguchi H, Tokuyama M etal. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol 2010;14:349-355.
8. Kuragano T, Matsumura O, Matsuda A etal. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014;86:645-854.
9. Rostoker G, Griuncelli M, Loridon C etal. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012;125:991-999.
10. Eleftheriadis T, Antoniadi G, Liakopoulos V etal. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007;20:440-451.
11. Shoji S, Inaba M, Tomosugi N etal. Greater potency of darbepoietin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013;90:237-244.
12. Kakimoto-Shino TY, Kuji T, Fujikawa T, Umemura S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Ther Apher Dial 2014;18:421-426.
13. Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial 2014;18:414-420.
14. Tsubakihara Y, Nishi S, Akiba T etal. 2008 Japanese Society for Dialysis Therapy: guideline for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-275.
15. Tomosugi N, Kawabata H, Wakatabe R etal. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381-1387.
16. Canoud B, Mingardi G, Braun J etal. Intravenous CERA maintains stable haemoglobin levels inpatients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-3661.
17. Carrera F, Lok CE, de Francisco A etal. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized competitive trial. Nephrol Dial Transplant 2010;25:4009-4017.
18. Jonckheere S, Dierick J, Vanhouteghem H etal. Erythrocyte indices in the assessment of iron status in dialysis-dependent patients with end-stage renal disease on continuous erythropoietin receptor activator versus epoetin beta therapy. Acta Haematol 2010;124:27-33.
19. Huebers HA, Beguin Y, Pootraku P etal. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102-107.
20. Lorenzo JD, Rodríguez MM, Martín SS, Romo JM. Assessment of erythropoiesis activity during hemodialysis therapy by soluble transferrin receptor levels and ferrokinetic measurements. Am J Kidney Dis 2001;37:550-556.
21. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
22. Kuragano T, Shimonaka Y, Kida A, Furuta M etal. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31:534-540.
23. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C etal. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009;22:70-77.
24. Tessitore N, Girelli D, Campostrini N etal. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010;25:3996-4002.
25. van der Weerd NC, Grooteman MP, Bots ML etal. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE 2012;7:e39783.
26. Eleftheriadis T, Pissas G, Remoundou M etal. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin. Int Urol Nephrol 2014;46:161-167.
27. van der Weerd NC, Grooteman MP, Bots ML etal. CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;28:3062-3071.